| Status | Study |
| Recruiting |
Study Name: Mast Cell Connect: A Registry for Patients With Mastocytosis Condition: Mastocytosis Date: 2015-11-19 |
| Recruiting |
Study Name: Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies Condition: Aggressive Systemic Mastocytosis Systemic Mastocytosis-associated Hematologic Non-mast Cell Date: 2015-09-15 Interventions: Drug: BLU-285 |
| Recruiting |
Study Name: Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Condition: Aggressive Systemic Mastocytosis Mast Cell Leukemia Date: 2015-03-24 Interventions: Drug: Ibrutinib Given PO |
| Completed |
Study Name: Patient-Reported Outcome Questionnaire for Systemic Mastocytosis Condition: Aggressive Systemic Mastocytosis (ASM) SM w Assoc Clonal Hema Non-mast Cell Lineage Disease Date: 2015-02-26 Interventions: Other: Interview Single interview lasting approximately one hour |
| Recruiting |
Study Name: Bioelectrical Impedance Measurement for Predicting Treatment Outcome in Patients With Newly Diagnosed Acute Leukemia Condition: Acute Undifferentiated Leukemia Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities Date: 2013-05-31 Interventions: Procedure: bioelectric impedance analysis Undergo bioelectric impedance analysis |
| Recruiting |
Study Name: Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Condition: Aggressive Systemic Mastocytosis Mast Cell Leukemia Date: 2013-03-05 Interventions: Drug: brentuximab vedotin Brentuximab vedotin is an antibody with a covalently attached toxin. The antib |
| Recruiting |
Study Name: Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Condition: Cancer Date: 2011-03-15 Interventions: Drug: ketamine hydrochloride Other: pharma |
| Recruiting |
Study Name: Study of Information Received About Fertility and Infertility in Patients Who Have Finished Treatment for Cancer Condition: Cancer Date: 2011-02-11 Interventions: Other: questionnaire administration Other: |
| Completed |
Study Name: Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies Condition: Acute Undifferentiated Leukemia Adult Acute Lymphoblastic Leukemia in Remission Date: 2011-01-07 Interventions: Drug: deferasirox Given orally |
| Completed |
Study Name: MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia Condition: Accelerated Phase Chronic Myelogenous Leukemia Acute Leukemias of Ambiguous Lineage Date: 2010-10-29 Interventions: Drug: Akt inhibitor MK2206 Giv |